Infectious Diseases
Antibiotics, antifungals, antivirals and other infectious disease pharmaceuticals account for a multibillion sector. The battle against contagious diseases takes places in a highly changeable environment, with a wealth of commercial opportunities arising from quickly emerging threats (e.g. avian flu) and the infectious disease and vaccination policies of national governments and international healthcare organisations. Keep track of the latest industry news and activity with the publications listed
under Research and Markets’ Infectious Diseases category.
Our reports, books, and subscriptions will allow you to explore licensing, patents, forecasts, market trends, clinical trials, and drug pipelines. Leading players featured in our publications include Pfizer, Roche, Novartis, AstraZeneca, Sanofi, Johnson & Johnson, Merck, Abbott, GlaxoSmithKline, Lilly, and more.
For publications about Infectious Disease Testing please visit the relevant category under Healthcare and Medical Devices.
Show Less
Read more
Rabies - Pipeline Review, H1 2013
Rabies – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Rabies - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Streptococcal Infections - Pipeline Review, H1 2013
Streptococcal Infections – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Streptococcal Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline....
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Global Malaria Pipeline Capsule - 2013
Fore Pharma's latest report ‘Global Malaria Pipeline Capsule – 2013' provides up-to-date information on key Research and Development (R&D) activities in the global malaria market It covers active malaria...
April
2013
FROM
EUR 528USD 690GBP 445AUD 734JPY 67,575SEK 4 569CHF 649CAD 717
Escherichia Coli Infections - Pipeline Review, H1 2013
Escherichia Coli Infections – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Escherichia Coli Infections - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic...
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Sepsis - Pipeline Review, H1 2013
Sepsis – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Sepsis - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information...
April
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
EpiCast Report: Dermatophytic Onychomycosis - Epidemiology Forecast to 2022 Dermatophytic onychomycosis (DO) is an infection of the nail fold or nail plate with dermatophytes, a type of fungus, especially...
March
2013
FROM
EUR 3,056USD 3,995GBP 2,575AUD 4,251JPY 391,252SEK 26 453CHF 3'759CAD 4,154
Dermatomycoses Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Dermatomycoses Global Clinical Trials Review, H1, 2013" provides data on the Dermatomycoses clinical trial...
March
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Cholera Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Cholera Global Clinical Trials Review, H1, 2013" provides data on the Cholera clinical trial scenario. This report...
March
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Trypanosomiasis Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Trypanosomiasis Global Clinical Trials Review, H1, 2013" provides data on the Trypanosomiasis clinical trial...
March
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Herpes Simplex Infections Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Herpes Simplex Infections Global Clinical Trials Review, H1, 2013" provides data on the Herpes...
March
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Gonorrhea Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Gonorrhea Global Clinical Trials Review, H1, 2013" provides data on the Gonorrhea clinical trial scenario. This...
March
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Leishmaniasis (Kala-Azar) Global Clinical Trials Review, H1, 2013" provides data on the Leishmaniasis...
March
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
PharmaFocus: Vaccine Adjuvants in Infectious Disease
Summary
Originally discovered by Glenny in the 1920s, vaccine adjuvants have remained the pharmaceutical industry’s “dirty little secret”. Today,...
March
2013
FROM
EUR 3,056USD 3,995GBP 2,575AUD 4,251JPY 391,252SEK 26 453CHF 3'759CAD 4,154
Cryptococcosis Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Cryptococcosis Global Clinical Trials Review, H1, 2013" provides data on the Cryptococcosis clinical trial...
March
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Herpes Zoster (Shingles) Global Clinical Trials Review, H1, 2013" provides data on the Herpes Zoster...
March
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
EpiCast Report: Hepatitis C Virus - Epidemiology Forecast to 2022 Hepatitis C is a largely asymptomatic liver disease caused by the hepatitis C virus (HCV) HCV is an escalating public health problem...
March
2013
FROM
EUR 3,056USD 3,995GBP 2,575AUD 4,251JPY 391,252SEK 26 453CHF 3'759CAD 4,154
Impetigo Global Clinical Trials Review, H1, 2013
Summary
Our clinical trial report, “Impetigo Global Clinical Trials Review, H1, 2013" provides data on the Impetigo clinical trial scenario. This report...
March
2013
FROM
EUR 1,912USD 2,500GBP 1,611AUD 2,660JPY 244,838SEK 16 554CHF 2'352CAD 2,600
Typhoid Fever - Pipeline Review, H1 2013
Typhoid Fever – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Typhoid Fever - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...
March
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Yellow Fever - Pipeline Review, H1 2013
Yellow Fever – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Yellow Fever - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides...
March
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
Bacterial Pneumonia - Pipeline Review, H1 2013
Bacterial Pneumonia – Pipeline Review, H1 2013
Summary
Global Markets Direct’s, 'Bacterial Pneumonia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This...
March
2013
FROM
EUR 1,530USD 2,000GBP 1,289AUD 2,128JPY 195,871SEK 13 243CHF 1'882CAD 2,080
